Overview

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center